Spain’s Grifols said the latest results from a clinical trial of the company’s Alzheimer’s treatment show positive effects by achieving a reduction of the disease’s progression in patients with mild and moderate conditions.
Takeda Pharmaceutical Co. trimmed the company’s full-year fiscal 2019 loss forecast on strong sales of core drugs and progress in consolidating with Shire Plc.
U.S. Food and Drug Administration Acting Commissioner Ned Sharpless said he plans to “maintain FDA’s current course of action in every area and proceed full-speed ahead,” according to a statement issued by the regulatory agency.
The Spanish blood products company Grifols signed a strategic alliance with Shanghai RAAS in an effort to increase sales of plasma-derived products in China.
SAB Therapeutics announced its first-in-human trial of new immunotherapy approach has shown efficacy in antibiotic-resistant bacteria based on a recent paper published online in Clinical Infectious Diseases.
